ASTRO Journals

Send us Fan Mail

Dr. Sue Yom, Editor in Chief, hosts Dr. Scott Soltys, Professor of Radiation Oncology from Stanford University and outgoing Section CNS Section Editor, along with Dr. Daniel Trifiletti, Associate Professor at Mayo Clinic Florida and CNS Associate Section Editor who first-authored this month’s OncoScan, entitled "Novel Applications of Stereotactic Radiosurgery Beyond Oncology: Prospective Trials in Functional Radiosurgery," and Dr. Valentina Pinzi, Senior Assistant in the Department of Neurosurgery Radiotherapy Unit of the Neurological Institute Carlo Besta in Milan, who is the lead author of an article in this month’s issue, "Hypofractionated Radiosurgery for Large or in Critical-Site Intracranial Meningioma: Results of a Phase 2 Prospective Study."

Send us Fan Mail

Practical Radiation Oncology section editor, Minsun Kim, Ph.D. of University of Washington, hosts a conversation on automated treatment planning to improve plan quality beyond human intuition. A senior author on the paper published in PRO: "Clinical acceptability of automated radiation treatment planning for head and neck cancer using the radiation planning assistant", Beth Beedle, MD, of Stanford University and the chair of the AAPM TG 308: "Clinical implementation of data-driven quality control and automated treatment planning", of University of California, San Diego, Kevin Moore, Ph.D. discuss the current status and recommendations for automated treatment planning approaches to ensure patient safety.

Send us Fan Mail

Editor-in-Chief Dr. Sue Yom hosts Dr. Shankar Siva, Associate Professor and Radiation Oncologist from the Peter MacCallum Cancer Centre, Australia and the supervising author of "Cost-Effectiveness of Single- versus Multi-Fraction SABR for Pulmonary Oligometastases - The SAFRON II Trial"; Dr. David Sher, Professor at the University of Texas Southwestern Medical Center and the Red Journal's Methodology Section Editor who first-authored this month's OncoScan "The Cost-Effectiveness of Consolidative Radiation Therapy in Oligometastatic Disease: High-Value Proposition or Wishful Thinking?"; and Dr. Aisling Barry, Professor and Chair of Radiation Oncology at University College Cork and Cork University Hospital, Ireland, who first-authored "The Impact of Disease Progression on Health-Related Quality of Life Outcomes in Patients with Oligo-Metastatic Disease at 12-Months post Stereotactic Body Radiotherapy."

Send us Fan Mail

Editor-in-Chief, Robert Amdur, MD, reviews a paper published in the November/December 2022 issue of PRO that presents the latest guidelines on CTV definition with postoperative radiotherapy for bladder cancer: "International Consensus Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy: Update From an IBIS Workgroup."

Send us Fan Mail

Editor-in-Chief, Robert Amdur, MD, explains the 2021 World Health Organization Classification of Adult Brain Gliomas and then comments on the guideline paper published in the September/October 2022 issue of PRO: "Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline."

Send us Fan Mail

Deputy Editor Dr. Salma Jabbour, Vice Chair of Clinical Research and Faculty Development and Clinical Chief in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey, hosts Dr. Matthias Guckenberger, Chairman and Professor of the Department of Radiation Oncology at the University Hospital Zurich and University of Zurich, discussing a new article from his European team, "Completeness of reporting oligometastatic disease characteristics in the literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature," and Dr. David Palma, Clinician Scientist II at the Ontario Institute for Cancer Research, Radiation Oncologist at the London Health Sciences Center, and Associate Professor at Western University, who was the supervising author on the 5-year update of the SABR-COMET trial, " Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) – Extended Long-Term Outcomes."

Send us Fan Mail

Dr. Jeffrey Olsen, Associate Professor of Radiation Oncology at the University of Colorado and section editor of our gastrointestinal section, co-leads a discussion along with our Editor-in-Chief Editor-in-Chief Dr. Sue Yom hosts Dr. Sara Alcorn, Associate Editor and Associate Professor of Radiation Oncology at the University of Minnesota, who first-authored this month’s Oncology Scan, Toxicity and Timing of Breast Radiotherapy with Overlapping Systemic Therapies and Dr. Jennifer Bellon, Section Editor for breast cancers. Director of Breast Radiation Oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and first author of a Red Journal paper from May 2022 called Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer, as well as Dr. Jeffrey Cao, Provincial Breast Tumour Team Lead for Alberta Health Services and Clinical Associate Professor at the University of Calgary, who supervised a new article in this month’s issue, Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study.